

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/786,015	02/26/2004	Tomoaki Hoshino	021310B	3534	
38834 759	38834 7590 10/04/2006			EXAMINER	
	I, HATTORI, DANIE	JIANG, DONG			
1250 CONNECTICUT AVENUE, NW SUITE 700 WASHINGTON, DC 20036			ART UNIT	PAPER NUMBER	
			1646		

DATE MAILED: 10/04/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		10/786,015	HOSHINO, TOMOAKI				
		Examiner	Art Unit				
		Dong Jiang	1646				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLICHEVER IS LONGER, FROM THE MAILING DISSIDERS OF THE MAILING DEPTH OF THE MAILING	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timwill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	I. lely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
2a)□	Responsive to communication(s) filed on <u>26 F</u> This action is FINAL . 2b) This Since this application is in condition for allowa closed in accordance with the practice under E	s action is non-final. nce except for formal matters, pro					
Dispositi	on of Claims						
5)□ 6)⊠ 7)□	Claim(s) 27 and 28 is/are pending in the application of the above claim(s) is/are withdray Claim(s) is/are allowed. Claim(s) 27 and 28 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	wn from consideration.					
Applicati	on Papers						
10)⊠	The specification is objected to by the Examine The drawing(s) filed on 26 February 2004 is/an Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Example 2015.	e: a) \square accepted or b) \boxtimes objected drawing(s) be held in abeyance. See tion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority u	ınder 35 U.S.C. § 119	•					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 10/257,965. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
2) 🔲 Notic	k(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08)	4) ☐ Interview Summary Paper No(s)/Mail Da 5) ☐ Notice of Informal P	ite				
Paper No(s)/Mail Date <u>2/26/04</u> . 6) ☐ Other:							

Applicant's preliminary amendment filed on 26 February 2004 is acknowledged and entered. Following the amendment, the original claims 1-26 and 29-31 are canceled.

Currently, claims 27 and 28 are pending and under consideration.

Formal Matters:

Information Disclosure Statement

Applicant's IDS submitted on 2/26/2004 is acknowledged and has been considered. A signed copy is attached hereto.

signed copy is distance nerver

Priority acknowledgement

This application claims benefit of U.S. application No. 10/257,965, which is acknowledged.

It is noted that this application also claims benefit to foreign applications in a language

other than English, and no English translation is supplied or found in the present application.

Drawings

This application lacks formal drawings. The informal drawings filed in this application are acceptable for examination purposes. When the application is allowed, applicant will be required to submit new formal drawings.

Appropriate correction is required.

Specification

The specification is objected to because it lacks the necessary reference to the prior application. A statement reading "This is a division of Application No. 10/257,965, filed 25 December 2002, now patent No. 6,555,319." should be entered following the title of the invention or as the first sentence of the specification.

Rejections under 35 U.S.C. 112:

4

Application/Control Number: 10/786,015

Art Unit: 1646

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 27 and 28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 27 is rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential elements/steps, such omission amounting to a gap between the elements/steps. See MPEP § 2172.01. The omitted elements/steps are: 1) dose, duration, route of administration, etc. to ensure the development of said interstitial pneumonia; 2) what steps to take or what/how to measure in order to determine the therapeutic effect of a potential remedy. The claim is further indefinite for the recitation "and screening a remedy for interstitial pneumonia" because it is unclear what is the relationship of this step to the step of "preparing an animal model", i.e., are they related, or does the screening require the use of said animal model?

Claim 28 is included in this rejection because it is dependent from the specifically mentioned claims without resolving the indefiniteness issue belonging thereto.

Prior Art:

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Arai et al. (J. Interferon & Cytokine Res., February 2000, 20 (2):217-24) discloses the effect of a combination of IL-18 and IL-2 on in vivo NK cell activation by studying mice administered with IL-18 and IL-2, and teaches that such a combined treatment resulted in a significant increase in the number of spleen NK cells and a marked enhancement of spleen NK cells activity, and contributed to inhibition of tumor metastasis without inducing significant toxicity (the abstract, page 219, the last paragraph, page 220, the left column, and Figures 3 and 5), indicating that the treatment (3 days) did not cause any significant organ disfunction/damage.

Conclusion:

No claim is allowed.

Application/Control Number: 10/786,015

Art Unit: 1646

Advisory Information:

Any inquiry concerning this communication should be directed to Dong Jiang whose telephone number is 571-272-0872. The examiner can normally be reached on Monday - Friday from 9:30 AM to 7:00 PM.

Page 4

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Dong Jiang, Ph.D. Patent Examiner

AU1646

9/20/06